Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Management Presentations to Focus on Depth of Product Pipeline
CORALVILLE, Iowa, Feb. 07, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March.
Details of KemPharm's presentations are as follows:
| Event: | BIO CEO & Investor Conference | |
| Date: | Tuesday, February 14, 2017 | |
| Time: | 11:30 a.m. (ET) | |
| Location: | The Waldorf Astoria, New York, NY |
| Event: | RBC Capital Markets 2017 Global Healthcare Conference | |
| Date: | Wednesday, February 22, 2017 | |
| Time: | 9:00 a.m. (ET) | |
| Location: | The New York Palace Hotel, New York, NY |
| Event: | Cowen & Co. 36th Annual Health Care Conference 2017 | |
| Date: | Tuesday, March 7, 2017 | |
| Time: | 8:00 a.m. (ET) | |
| Location: | The Boston Marriott Copley Place, Boston, MA |
| Event: | 29th Annual ROTH Conference | |
| Date: | Conference Date March 12-15, 2017 | |
| Time: | Presentation date/time to be scheduled | |
| Location: | The Ritz Carlton, Dana Point, CA |
| Event: | Oppenheimer & Co. 27th Annual Healthcare Conference | |
| Date: | Tuesday, March 21, 2017 | |
| Time: | 9:45 a.m. (ET) | |
| Location: | The Westin New York Grand Central, New York, NY |
All presentation webcasts will available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/ following delivery at the respective conferences.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
